株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

服薬遵守についての新しい考え方

New Thinking in Patient Adherence

発行 FirstWord 商品コード 233470
出版日 ページ情報 英文 62 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
服薬遵守についての新しい考え方 New Thinking in Patient Adherence
出版日: 2012年03月08日 ページ情報: 英文 62 Pages
概要

患者の服薬不遵守は、米国だけでも毎年2900億米ドルに上ると見積もられています。消費者が服薬を遵守しない理由はさまざまですが、80%の人々が、意図的に処方薬を指示通りに服用していません。

当レポートでは、患者の服薬遵守について包括的に調査し、消費者が医師の指示に従わない理由、主な服薬遵守の動向、製薬企業による薬剤師・医師・保険者との協力、医療制度、および最新の服薬遵守戦略・ソリューション・技術革新などについて分析しており、、概略以下の構成でお届けします。

エグゼクティブ・サマリー

イントロダクション

医療遵守の好ましい動向

  • 医療効果への注目
  • ステークホルダー間の大きな調整
  • 欧州におけるイニシアチブ
  • 米国の将来予測

製薬企業との協力

  • 薬剤師との協力
  • GSKによる地域への働きかけチーム
  • 薬局改革
  • 企業との協力およびヘルスケアシステム
  • 患者経路の共同制作
  • 仲介者を通した協力
  • 患者負担金
  • 医師との協力
  • DAWN からの分析

服薬遵守ソリューション

  • 患者の生活をシンプルにする
  • パッケージングソリューション
  • 薬ビン
  • スマートピル
  • 医薬管理
  • ドラッグデリバリー
  • リマインダーおよびエデュケーションプログラム
  • ケーススタディ:Prolong

モバイルヘルス

  • MyAsthma アプリケーション
  • 遠隔モニタリング

服薬遵守対応の再構築

  • 服薬遵守イニシアチブの組織
  • 中心となる服薬遵守の取り組み
  • 規則よりも例外
  • 服薬遵守の課題
  • 服薬遵守の測定
  • 今後の展望

承認

専門家の見解

目次
Product Code: 400200087

Patient non-adherence is estimated to represent $290 billion per year in avoidable medical expenses in the United States alone. Consumers' motivations for non-compliance are complex; up to 80% of people are intentionally not taking their prescription drugs as directed.

There is no better time for pharma companies to reflect on their patient-adherence strategies. Not only is it more cost-effective to focus on retaining, rather than acquiring, customers, but it is also an ideal way of working with other stakeholders, as patient-centric policies are implemented in healthcare systems round the world. Moreover, digital innovations are creating new opportunities for stakeholders to join forces in a concerted effort to educate patients about why taking their medications is so essential to their health.

Overview

‘New Thinking in Patient Adherence’ goes far beyond presenting data on consumer behaviour. This comprehensive and insightful report reveals a shift towards a more holistic approach to the problem, and reviews a wealth of innovative tactics that are being used to address compliance and persistence issues worldwide. You'll learn about new ways that leading pharmaceutical companies are collaborating with other healthcare stakeholders, including clinicians, pharmacists, payers, and health systems. This up-to-the-minute report also provides details on effective educational initiatives, and the very latest technological solutions, including smart pills and packaging, mobile applications, and remote monitoring.

Key Report Features

  • Roundup of the latest intelligence on why consumers do not follow doctors' orders
  • Leading adherence trends - focus on clinical outcomes, and greater coordination among stakeholders (with insights from Novo Nordisk's DAWN study - showing that collaboration with stakeholders is key)
  • Detailed examination of pharma collaborations with pharmacists, physicians, payers, and health systems
  • Latest adherence strategies, solutions, and technological innovations

Key Benefits

  • How pioneering pharma companies, including GlaxoSmithKline and Merck, are reorganising to prioritise adherence initiatives
  • Practical strategies and tactics to address adherence issues
  • Up-to-the-minute view of the latest available solutions

Key Questions Answered

  • Why have so many adherence interventions failed?
  • How are new technologies being harnessed to improve adherence?
  • What economic factors are driving adherence-focused collaborations between pharma companies and insurers?
  • How are the critical roles in patient adherence played by primary care physicians and pharmacists changing?

Who Would Benefit From This Report?

This report will be of value to senior pharma directors and managers with responsibilities in the following areas:

  • Market access
  • Patient adherence
  • Pricing and reimbursement
  • Key account and territory management
  • Marketing, brand and sales management
  • Consumer marketing solutions
  • Advertising and promotion
  • Business development
  • CRM and relationship marketing
  • Multi-channel marketing
  • Strategic brand planning solutions
  • Forecasting and marketing professionals

The report will also benefit providers of consultancy and technology services and solutions for patient education and adherence, relationship marketing and market research.

Table of Contents

Executive summary

Introduction

  • Non-adherence has deep roots
  • Narrow focus of research
  • Effectiveness of adherence interventions
  • Barriers to adherence
  • Intentional and unintentional factors
  • Various shades of grey
  • A challenge for pharma

Trends favouring medical adherence

  • Focus on health outcomes
  • Greater coordination among stakeholders
  • Initiatives in Europe
  • Script your Future in the US

Pharma collaborations

  • with pharmacists
  • GSK's Community Outreach Team
  • Pharmacy innovation
  • with payers and healthcare systems
  • Collaborating on patient pathways
  • Collaboration via an intermediary
  • Co-pays
  • with physicians
  • Insights from DAWN

Adherence solutions

  • Making life simpler for the patient
  • Packaging solutions
  • Pill bottles
  • Smart pills
  • Medication management
  • Drug delivery
  • Reminders and education programmes
  • Case study: Prolong

Mobile health

  • MyAsthma app
  • Remote monitoring

Restructuring to tackle adherence

  • Organisation of adherence initiatives
  • Central adherence efforts
  • Exception rather than the rule
  • Owning the adherence challenge
  • Measuring adherence
  • The way forward

Acknowledgements

Expert Views Include:

  • Colleen A McHorney, senior director of US Outcomes Research, Merck
  • Søren Skovlund, head of the DAWN programme, Novo Nordisk
  • Chris Preti, head of Patient Engagement group, GlaxoSmithKline
  • Oliver Johnston, European head of marketing at Plovia, GlaxoSmithKline
  • Francisco Abad, Seretide marketing manager, GlaxoSmithKline
  • Thomas Forissier, principal, Life Sciences Strategy, CapGemini Consulting
  • Vernon F Schabert, principal, Health Economics and Outcomes Research, IMS Consulting
  • Walter Berghahn, executive director, Healthcare Compliance Packaging Council
  • Dr Michael Ackermann, senior vice president, Global Commercial Solutions, Quintiles
  • Greg Muffler, CEO, CellepathicRx
  • Rebecca Burkholder, vice-president, Health Policy, National Consumers League
  • Carole North, director, 90TEN Healthcare
Back to Top